araag2/HINT huggingface dataset:
Clinical trial NCT02449343 (phase 2/phase 3, status: unknown status)
Conditions: soft tissue sarcoma
ICD codes: C46.1
Drugs: anlotinib, placebo
SMILES: [H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(O)C(OC)=C1)C1=CC3=C(OCO3)C=C1[C@H]2O[C@@H]1O[C@]2([H])CO[C@@H](C)O[C@@]2([H])[C@H](O)[C@H]1O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Signed and dated informed consent

          -  Histological documentation of Soft Tissue Sarcoma,including Synovial
             sarcoma、Leiomyosarcoma、Alveolar soft part sarcoma、Undifferentiated pleomorphic
             sarcoma/malignant fibrous histiocytoma、Adipocytic Tumors、Fibrosarcoma、Clear cell
             sarcoma、Epithelioid sarcoma，With measurable disease.

          -  Within the past 6 months, using at least one failure of chemotherapy regimens
             (including anthracycline-based) in treating patients(except alveolar soft part
             sarcoma)

          -  18-70years,ECOG PS:0-1,Life expectancy of more than 3 months

          -  Main organs function is normal

          -  The woman patients of childbearing age who must agree to take contraceptive methods
             (e.g. intrauterine device, contraceptive pill or condom) during the research and
             within another 6 months after it; who are not in the lactation period and examined as
             negative in blood serum test or urine pregnancy test within 7 days before the
             research; The man patients who must agree to take contraceptive methods during the
             research and within another 6 months after it

        Exclusion Criteria:

          -  Prior treatment with Anlotinib

          -  With pleural effusion or ascites, cause respiratory syndrome

          -  Accepted the vascular endothelial growth inhibitor class targeted drug treatment of
             patients

          -  Plan to take systemic anti-tumor therapy within 4 weeks before grouping or during the
             medicine-taking period of this research, including Cytotoxic Therapy, Signal
             Transduction Inhibitor, and Immunotherapy (or who use Mitomycin C within 6 weeks
             before taking the treatment with experimental drug); The patients who have already
             taken Extended Field Radiotherapy (EF-RT) within 4 weeks before grouping or Limited
             Field Radiotherapy with proposed assessment of nidus within 2 weeks before grouping

          -  Symptoms of brain metastases cannot be controlled and treated within less than 2
             months

          -  With severe and failed to controlled diseases

          -  Occurred venous thromboembolic events within 6 months
Clinical trial NCT02450539 (phase 2, status: completed)
Conditions: non-small cell lung cancer stage iv
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: abemaciclib, docetaxel
SMILES: CCN1CCN(CC2=CC=C(NC3=NC=C(F)C(=N3)C3=CC(F)=C4N=C(C)N(C(C)C)C4=C3)N=C2)CC1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed diagnosis of stage IV NSCLC.

          -  Have progressed during or after platinum-based chemotherapy for advanced disease.

          -  Have not received prior treatment with docetaxel.

          -  Have availability of adequate formalin-fixed paraffin-embedded (FFPE) tumor derived
             material.

          -  Have adequate organ function including hematology, renal, and liver.

          -  Have good performance score (0-1).

          -  Have measureable disease per RECIST 1.1.

          -  Agree to use a reliable medically approved method of birth control.

        Exclusion Criteria:

          -  Have received prior treatment with any cyclin dependent kinase (CDK) 4 and 6 inhibitor
             or participated in a clinical trial with a CDK 4 and 6 inhibitor and the treatment
             administered is not known.

          -  Are currently receiving treatment in a clinical trial involving an investigational
             product or non-approved use of a drug or device.

          -  Have the presence of unstable central nervous system (CNS) metastasis.

          -  Have had major surgery (excluding biopsy) < 28 days of the initial dose of study drug.
Clinical trial NCT02450903 (phase 2, status: completed)
Conditions: non-small-cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: ldk378
SMILES: CC(C)OC1=C(NC2=NC=C(Cl)C(N2)=NC2=CC=CC=C2S(=O)(=O)C(C)C)C=C(C)C(=C1)C1CCNCC1
Eligibility criteria:

        Key Inclusion Criteria:

          -  Histologically or cytologically confirmed diagnosis of Stage IIIb or IV NSCLC that
             carries an ALK rearrangement as determined locally by Vysis ALK Break Apart FISH Probe
             Kit (Abbott Molecular Inc.) test.

          -  Patients must have NSCLC that has progressed at study enrollment.

          -  Patients must have received previous treatment with alectinib for treatment of locally
             advanced or metastatic NSCLC. Prior therapy with crizotinib as ALK inhibitor therapy
             in addition to alectinib is allowed. Alectinib doesn't need to be the last therapy
             prior to study enrollment. No particular sequence of prior alectinib and crizotinib is
             required for enrollment.

          -  Patients must be chemotherapy-naïve or have received only one line of prior cytotoxic
             chemotherapy.

          -  Age 18 years or older at the time of informed consent.

        Key Exclusion Criteria:

          -  Patients with known hypersensitivity to any of the excipients of LDK378.

          -  Prior therapy with other ALK inhibitor investigational agents except crizotinib and
             alectinib.

          -  Prior systemic anti-cancer (including investigational) therapy aside from alectinib,
             crizotinib and one regimen of previous cytotoxic chemotherapy for locally advanced or
             metastatic NSCLC.

          -  Patients with symptomatic central nervous system (CNS) metastases who are
             neurologically unstable or have required increasing doses of steroids within the 2
             weeks prior to study entry to manage CNS symptoms.

          -  Patient with history of interstitial lung disease or interstitial pneumonitis,
             including clinically significant radiation pneumonitis.

          -  Patients with history of carcinomatous meningitis.

          -  Patient with a concurrent malignancy or history of a malignant disease other than
             NSCLC that has been diagnosed and/or required therapy within the past 3 years.

          -  Patient has clinically significant, uncontrolled heart disease and/or recent cardiac
             event (within 6 months)
Clinical trial NCT02452060 (phase 2/phase 3, status: completed)
Conditions: pain, postoperative depression
ICD codes: N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52
Drugs: ketamine
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          1. Adults, >18 years, <65 years, who will undergo gastric bypass or sleeve gastrectomy.

          2. Subject is non-lactating and is either:

               -  Not of childbearing potential; or

               -  Of childbearing potential but is not pregnant at time of baseline as determined
                  by pre-operative pregnancy testing.

          3. Subject is ASA physical status 1, 2, or 3.

          4. Subject who is deemed medically stable

        Exclusion Criteria:

          1. <18 years of age; >65 years of age

          2. Pregnant or breastfeeding

          3. Does not speak or understand English (the study forms used are copy-righted in
             English)

          4. Cognitively impairment (by history) or clinical signs of altered mental status

          5. History of misuse or abuse of ketamine

          6. History of chest pain or chest pain in the PACU

          7. Use of a medication that interferes with metabolism of ketamine within the last 24
             hours

          8. A diagnosis of schizophrenia and/ or a history of chronic antipsychotic medication use

          9. History of head trauma

         10. History of intracranial mass or hemorrhage

         11. History of stroke

         12. History of cardiac arrhythmia

         13. Subject for whom ketamine is contraindicated

         14. Unwillingness to give informed consent according to HIC guidelines
Clinical trial NCT02453711 (phase 2, status: completed)
Conditions: metabolism and nutrition disorder, obesity
ICD codes: E70.5, E71.32, E72.4, E76.9, E78.89, E83.2, E88.40, E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211
Drugs: semaglutide, liraglutide, placebo
SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O, CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria: - Informed consent obtained before any trial-related activities.
        Trial-related activities are any procedures that are carried out as part of the trial,
        including activities to determine suitability for the trial - Male or female, age 18 years
        or older at the time of signing inform consent - Body mass index (BMI) equal or above 30.0
        kg/m^2 at the screening visit - At least one unsuccessful weight loss attempt per
        investigator judgement Exclusion Criteria: - A HbA1c (glycosylated haemoglobin) equal to or
        above 6.5% at screening or diagnosed with type 1 or type 2 diabetes mellitus - Treatment
        with glucose lowering agent(s) within 90 days before screening - Screening calcitonin equal
        to or above 50 ng/L (pg/mL) - Personal or family history of medullary thyroid carcinoma or
        multiple endocrine neoplasia syndrome type 2 - History of pancreatitis (acute or chronic) -
        Obesity induced by endocrine disorders (e.g. Cushing Syndrome) - Treatment with any
        medication within 90 days before screening that based on investigator's judgement may cause
        significant weight change - Previous surgical treatment for obesity (liposuction and/or
        abdominoplasty performed 1 year before screening is allowed) - History of major depressive
        disorder within 2 years before randomisation - Any lifetime history of a suicidal attempt -
        Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing
        potential and not using an adequate contraceptive method (adequate contraceptive measures
        as required by local regulation or practice)
Clinical trial NCT02455999 (phase 2, status: completed)
Conditions: ocular pain, dry eye syndrome
ICD codes: H57.13, H57.10, H57.11, H57.12, H04.121, H04.122, H04.123, H04.129
Drugs: syl1001, syl1001, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Give written informed consent to participate in the study, after having received all
             information relating to the design, aims and possible risks resulting therefrom.

          -  Common symptoms of persistent, daily, mild to moderate dry eye lasting more than three
             months: OSDI scale between 13-70 and VAS scale between 2 -7.

          -  Eye tests in both eyes: Corneal fluorescein staining (Oxford scale > 0), Tear break-up
             time < 10 seconds and Schirmer's test with anaesthesia < 10 mm/5min.

        Exclusion criteria:

          -  Women who are pregnant or breastfeeding or who have a positive urine pregnancy test.
             Women who do not commit to use a medically acceptable method of contraception from the
             time of selection and throughout the study.

          -  Any current, relevant disease, including respiratory disease, cardiovascular disease,
             endocrine disease, neurological disease, haematological disease, kidney disease,
             oncological disease, liver disease, gastrointestinal dysfunction, hypertension or
             active acute infectious processes.

          -  Previous chronic or recurrent processes which, according to the investigator, could
             affect the development of the study.

          -  Concomitant use of other medications with analgesic activity by any route of
             administration at the time of entry into the study.

          -  Change in any concomitant eye and/or systemic medication of the patient one month
             before the study and during the study.

          -  Changes in the pre-established administration schedule of artificial tears during the
             15 days before the study and during the 10 days of the study.

          -  Initiation of treatment with cyclosporine or changes in the dosage or administration
             schedule of cyclosporine within the 6 months before inclusion in the study.

          -  History of hypersensitivity to drugs.

          -  Use of contact lenses during the treatment and previous 15 days.

          -  History of drug abuse or drug or alcohol dependence.

          -  Laboratory abnormalities which, in the investigator's opinion, are clinically
             significant.

          -  Previous refractive surgery.

          -  Having participated in another clinical trial within the 2 months prior to inclusion.

          -  Another eye disease that is significant in the investigator's opinion.
Clinical trial NCT02456714 (phase 2, status: completed)
Conditions: cholangiocarcinoma
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: folfirinox
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histological or cytological diagnosis of cholangiocarcinoma.

          -  Metastatic disease or irresectable locally advanced cholangiocarcinoma.

          -  Measurable disease according RECIST criteria version 1.1.

          -  Age from 18 to 75 year.

          -  WHO/ECOG performance status 0-2.

          -  Patients who received at least 3 cycles of gemcitabine/cisplatin in the first line.

          -  Adequate hematological function (WBC > 3.0 x 109/L, platelets > 100 x109/L)

          -  Adequate hepatic function (bilirubin ≤ 1.5 x upper normal limit (ULN); ALAT or ASAT
             <5x ULN in case of liver metastases and < 2.5 x ULN in absence of liver metastases.

          -  Adequate renal function (creatinine clearance > 60 ml/min; creatinine <120 µmol/L)

          -  Absence of cardiac insufficiency, chest pain (not medically controlled) and myocardial
             infarction in the 12 months preceding study entry.

          -  Signed informed consent.

        Exclusion Criteria:

          -  Concurrent secondary malignancies or other malignancies within 3 years prior to enter
             this study with the exception of non-metastatic basal cell or squamous cell skin
             cancer or carcinoma in situ of the cervix treated by cone-biopsy or resection

          -  Presence of cerebral or meningeal metastases

          -  Contraindication to any of the substances of the planned treatment.

          -  History of chronic diarrhea or colorectal inflammatory conditions, or of unresolved
             occlusion or sub-occlusion for which symptomatic treatment is being administered

          -  Active infection or other serious underlying conditions which may prevent the patient
             from receiving the planned treatment. For example: prolonged unresolved bacterial
             cholangitis with destruction of bile duct branches (e.g. after endoprosthesis
             insertion) or two or more cholangitis in the last 6 months. Patients with other active
             or uncontrolled severe infection, cirrhosis or chronic active hepatitis will be
             excluded.

          -  Presence of cardiac insufficiency, unstable angina pectoris, symptomatic congestive
             heart, failure myocardial infarction 6 months prior to randomization, serious
             uncontrolled cardiac arrhythmia.

          -  Inclusion in another investigational clinical trial

          -  Women who are pregnant, breast-feeding or not using adequate contraceptive

          -  Age younger than 18 or older than 76 years

          -  Individuals under correctional supervision or guardianship
Clinical trial NCT02459899 (phase 2, status: completed)
Conditions: type 1 diabetes mellitus
ICD codes: E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: placebo, sotagliflozin
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Participant had given written informed consent to participate in the study in
             accordance with local regulations.

          -  Adult participants 18 years and older with a diagnosis of type 1 diabetes mellitus
             (T1D) made at least 1 year prior to informed consent.

          -  Participants were being treated with insulin or insulin analog delivered via
             continuous subcutaneous insulin infusion (CSII) or multiple daily injection (MDI).

          -  At the Screening Visit, A1C had to be between 7.0% and 10.0%.

          -  Females of childbearing potential had to use an adequate method of contraception and
             have a negative pregnancy test.

        Exclusion Criteria:

          -  Use of antidiabetic agent other than insulin or insulin analog at the time of
             screening.

          -  Use of sodium-glucose cotransporter (SGLT) inhibitors within 8 weeks prior to
             screening.

          -  Chronic systemic corticosteroid use.

          -  Type 2 diabetes mellitus (T2DM), or severely uncontrolled T1D as determined by the
             Investigator.
Clinical trial NCT02461134 (phase 2, status: terminated)
Conditions: chronic graft versus host disease
ICD codes: D89.811, D89.812
Drugs: ponesimod
SMILES: CCC\N=C1/S\C(=C/C2=CC=C(OC[C@H](O)CO)C(Cl)=C2)C(=O)N1C1=CC=CC=C1C
Reason stopped: 
    low recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Signed informed consent

          -  Symptomatic moderate or severe chronic GVHD patients in need of a change of systemic
             immunosuppressant (IS) therapy

          -  Women of child bearing potential must have a negative pregnancy test and use reliable
             methods of contraception

        Exclusion Criteria:

          -  Clinically significant medical conditions including active or uncontrolled infections,
             new or recurrent malignancy, serious cardiac, pulmonary, or renal disease, and
             uncontrolled diabetes.

          -  Karnofsky Performance Score < 60.

          -  Immunosuppressant therapies other than allowed background therapy

          -  Anti-arrhythmic and heart rate lowering drugs.

          -  Any other circumstances or conditions, which, in the opinion of the investigator, may
             affect full participation in the study or compliance with the protocol
Clinical trial NCT02464046 (phase 2, status: completed)
Conditions: insomnia
ICD codes: F51.01, F51.02, F51.03, F51.04, G47.00, G47.09, A81.83
Drugs: jnj-42847922, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Healthy male and female participants aged between 18 and 65 years, inclusive

          -  Body mass index (BMI) between 18 and 30 kilogram per square meters (kg/m^2) inclusive
             (BMI = weight/height^2)

          -  Insomnia Severity Index (ISI) score more than or equal to (>=) 15 at screening

          -  Insomnia: at screening participants will report both difficulties with sleep onset and
             sleep maintenance. Insomnia will furthermore objectively be established prior to
             enrollment per PSG recorded over 3 consecutive nights. Participants will sleep for 3
             consecutive nights in the sleep center. First and second night data will be used to
             exclude any participant with restless leg syndrome, apnea, parasomnias or other sleep
             disorders. On the second and third night participants are required to meet objective
             inclusion criteria: 2-night mean LPS of >=30 minutes with no night <20 minutes, and on
             both nights TST <=6 hours and wake after sleep onset (WASO) >30 minutes

          -  Participants must be healthy / medically stable on the basis of clinical laboratory
             tests, medical history, vital signs, and 12-lead electrocardiogram (ECG) performed at
             screening and baseline

        Exclusion Criteria:

          -  Participant has current signs/symptoms of, liver or renal insufficiency;
             hypothyroidism or hyperthyroidism, significant cardiac, vascular, pulmonary,
             gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, or metabolic
             disturbances. Participants with non-insulin dependent diabetes mellitus who are
             adequately controlled (not on insulin) may participate in the study

          -  History of epilepsy or fits or unexplained black-outs

          -  Clinically significant abnormal values for hematology, clinical chemistry or
             urinalysis at screening or admission

          -  Clinically significant abnormal physical and neurological examination, vital signs or
             12-lead ECG at screening or baseline

          -  Smoking >=10 cigarettes/daily

          -  Insomnia related to restless leg syndrome, sleep breathing disorder, narcolepsy,
             obstructive sleep apnea/hypopnea, central sleep apnea, sleep-related hypoventilation,
             circadian rhythm sleep-wake disorders, substance/medication-induced sleep disorder or
             parasomnias

          -  Night-shift worker or significantly shifted diurnal activity pattern